Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Meningococcal
Findings from GlaxoSmithKline provide new insights into meningococcal
February 11th, 2009
According to recent research from Rixensart, Belgium, "Development of meningococcal serogroups A, C, W-135 and Y conjugate vaccines Could expand coverage against devastating meningococcal diseases. The immunogenicity of one dose of each one of five MenACWY-TT formulations versus a licensed ACWY polysaccharide vaccine was evaluated in 175 healthy Subjects of 15-25 years." "Serum bactericidal titers (rSBA) were evaluated before and after vaccination. The percentage of rSBA responders to each serogroup A, C, W-135 and Y did not statistically differ from the control for each of the five formulations except for serogroup A that was lower after administration of one...
Source: Vaccine Weekly (2009-02-11)
|
